Session Abstract – PMWC 2022 Silicon Valley

Join us as we share the latest on respiratory variant trends, and as we discuss how health systems and other organizations can leverage learnings from these past two years as we look beyond the pandemic and towards enabling healthier outcomes for entire communities now and into the future.

 Session Chair Profile

M.D., Ph.D., CEO, Helix

Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Powered by our proprietary Exome+® assay, Helix offers health systems a scalable solution that enables the discovery of medically relevant, potentially life-saving, genetic Information. Prior to Helix, James was a faculty member at Duke University where he focused on translational genomics and machine learning methodologies for EMRs. James has explored research topics in population genetics, Mendelian genomics, and computational psychiatry.

Experiences from the Front Lines of a National Viral Surveillance Organization
Join us as we share the latest on respiratory variant trends. We'll discuss how healthcare organizations can leverage learnings to inform predictive analytics and provide real-world evidence, as we look beyond the pandemic and towards enabling healthier outcomes for communities now and into the future.

 Speaker Profile

Ph.D., CEO, Pandemic Prevention Institute & Senior Vice President, Pandemic Prevention & Response, Health Initiative, The Rockefeller Foundation

Dr. Bright is a renowned immunologist, vaccine researcher and public health expert. In 2021, he joined The Rockefeller Foundation to lead the launch of the Pandemic Prevention Institute, a cutting-edge, multisectoral, initiative working to develop a global early warning system that works for all. Dr. Bright served as the Deputy Assistant Secretary for Preparedness and Response and the Director of the Biomedical Advanced Research and Development Authority (BARDA) in the U.S. Department of Health and Human Services. Dr. Bright served as vice president of Novovax global influenza programs and vaccine research and development. An international subject matter expert in biodefense, emergency preparedness and response, and pharmaceutical innovation. he served as an advisor to the Biden Administration, World Health Organization, and the Coalition for Epidemic Preparedness Innovations (CEPI).and the National Academies of Sciences, Engineering & Medicine Forum on Microbial Threats. He serves as a Sr. Fellow at the Foreign Policy Association.